Galecto option deal doubles Bristol-Myers IPF portfolio
This article was originally published in Scrip
Bristol-Myers Squibb signed a deal worth up to $444m with Galecto Biotech that gives the US big pharma company an option to buy Galecto and adds a second idiopathic pulmonary fibrosis (IPF) drug to the BMS pipeline.
You may also be interested in...
Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.